Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
View/ Open
Date
2016-02-09ICR Author
Author
Silvestri, V
Barrowdale, D
Mulligan, AM
Neuhausen, SL
Fox, S
Karlan, BY
Mitchell, G
James, P
Thull, DL
Zorn, KK
Carter, NJ
Nathanson, KL
Domchek, SM
Rebbeck, TR
Ramus, SJ
Nussbaum, RL
Olopade, OI
Rantala, J
Yoon, S-Y
Caligo, MA
Spugnesi, L
Bojesen, A
Pedersen, IS
Thomassen, M
Jensen, UB
Toland, AE
Senter, L
Andrulis, IL
Glendon, G
Hulick, PJ
Imyanitov, EN
Greene, MH
Mai, PL
Singer, CF
Rappaport-Fuerhauser, C
Kramer, G
Vijai, J
Offit, K
Robson, M
Lincoln, A
Jacobs, L
Machackova, E
Foretova, L
Navratilova, M
Vasickova, P
Couch, FJ
Hallberg, E
Ruddy, KJ
Sharma, P
Kim, S-W
kConFab Investigators,
Teixeira, MR
Pinto, P
Montagna, M
Matricardi, L
Arason, A
Johannsson, OT
Barkardottir, RB
Jakubowska, A
Lubinski, J
Izquierdo, A
Pujana, MA
Balmaña, J
Diez, O
Ivady, G
Papp, J
Olah, E
Kwong, A
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON),
Nevanlinna, H
Aittomäki, K
Perez Segura, P
Caldes, T
Van Maerken, T
Poppe, B
Claes, KBM
Isaacs, C
Elan, C
Lasset, C
Stoppa-Lyonnet, D
Barjhoux, L
Belotti, M
Meindl, A
Gehrig, A
Sutter, C
Engel, C
Niederacher, D
Steinemann, D
Hahnen, E
Kast, K
Arnold, N
Varon-Mateeva, R
Wand, D
Godwin, AK
Evans, DG
Frost, D
Perkins, J
Adlard, J
Izatt, L
Platte, R
Eeles, R
Ellis, S
EMBRACE,
Hamann, U
Garber, J
Fostira, F
Fountzilas, G
Pasini, B
Giannini, G
Rizzolo, P
Russo, A
Cortesi, L
Papi, L
Varesco, L
Palli, D
Zanna, I
Savarese, A
Radice, P
Manoukian, S
Peissel, B
Barile, M
Bonanni, B
Viel, A
Pensotti, V
Tommasi, S
Peterlongo, P
Weitzel, JN
Osorio, A
Benitez, J
McGuffog, L
Healey, S
Gerdes, A-M
Ejlertsen, B
Hansen, TVO
Steele, L
Ding, YC
Tung, N
Janavicius, R
Goldgar, DE
Buys, SS
Daly, MB
Bane, A
Terry, MB
John, EM
Southey, M
Easton, DF
Chenevix-Trench, G
Antoniou, AC
Ottini, L
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). METHODS: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)). CONCLUSIONS: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
Collections
Subject
kConFab Investigators
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
EMBRACE
Humans
Breast Neoplasms
Breast Neoplasms, Male
Genetic Predisposition to Disease
BRCA1 Protein
BRCA2 Protein
Neoplasm Staging
Mutation
Polymorphism, Single Nucleotide
Adult
Aged
Middle Aged
Female
Male
Research team
Oncogenetics
Language
eng
Date accepted
2016-01-06
License start date
2016-02-09
Citation
Breast cancer research : BCR, 2016, 18 (1), pp. 15 - ?
Publisher
BMC
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36
Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; et al. (FERRATA STORTI FOUNDATION, 2016-10-01) -
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Haviland, JS; Hopwood, P; Mills, J; Sydenham, M; Bliss, JM; et al. (ELSEVIER SCIENCE LONDON, 2016-06-01)AIMS: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data ... -
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial
Coles, C; Griffin, C; Kirby, A; Titley, J; Agrawal, R; et al. (2017-05-15)